GLP1R and Parkinson disease: Another compound with promising effect in targeting neuroinflammation in PD is semaglutide, a synthetic analogue of glucagon-like peptide 1 (GLP1), which stimulates GLP1R, and it is already used to treat type 2 diabetes.